On the other hand, checkpoint blockade targeting the PD-1/PD-L1 and CTLA-4 inhibitory axis has produced remarkable results in tumor treatment, and the clinical benefits are considered to mainly be based on the reactivation of exhausted T cells [168]. Here, PDCD1 is linked to neoplasm.